Evolution-Inspired drug sequence aims to outsmart breast cancer
NCT ID NCT06409390
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests a new way of giving several already-approved chemotherapy drugs in a specific order to treat hormone-positive metastatic breast cancer. The idea is to hit the cancer with a 'first strike' and then a 'second strike' to make treatment more effective. The study will enroll 15 women to see if this approach is practical and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel, Cyclophosphamide, Trastuzumab deruxtecan, Sacituzumab govitecan, Capecitabine, Fulvestrant
What this could lead to
If successful, this approach could offer a more effective way to control metastatic breast cancer by using existing drugs in a strategic sequence.
What could go wrong
This is a very small pilot study with only 15 participants, so results may not apply broadly. The treatment involves multiple chemotherapy drugs with known side effects like fatigue, nausea, and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact